NCT03447873View on ClinicalTrials.gov

Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)

PHASE4CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

September 15, 2020

Study Completion Date

February 3, 2021

Conditions

HIV Infections

Interventions

DRUG

Continue with triple therapy

To continue with triple therapy

DRUG

Switch to DTG + 3TC

Switch to dolutegravir + lamivudine once daily

DRUG

Switch to DRV/cobicistat + 3TC

Switch to darunavir/cobicistat + lamivudine once daily

Trial Locations (1)

41013

Virgen del Rocio University Hospital, Seville

All Listed Sponsors

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Hospitales Universitarios Virgen del Rocío

OTHER

NCT03447873 - Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual) | Biotech Hunter | Biotech Hunter